查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
呼吸道疾病基因檢測市場 - 全球和區域分析：按產品、按疾病類型、按技術、按性狀類型、按年齡層、按最終用戶、按國家分析：分析和預測（2023-2033）
市場調查報告書
商品編碼
1375827

呼吸道疾病基因檢測市場 - 全球和區域分析：按產品、按疾病類型、按技術、按性狀類型、按年齡層、按最終用戶、按國家分析：分析和預測（2023-2033）

Respiratory Disease Genetic Testing Market - A Global and Regional Analysis: Focus on Offerings, Specialty Type, Trait Type, Test Type Technology, Age Group, End User, and Country Analysis - Analysis and Forecast, 2023-2033
出版日期: 按訂單生產 | 出版商: BIS Research | 英文 | 商品交期: 7-10個工作天內

價格
簡介目錄

呼吸系統疾病仍然是全球健康問題，對患者福祉和醫療保健系統產生重大影響。

基因檢測已成為了解各種呼吸道疾病遺傳背景的重要工具。

呼吸系統疾病是包括氣喘、慢性阻塞性肺病（COPD）、囊腫纖維化和間質性肺病等多樣的疾病群。遺傳學在呼吸系統疾病發生和進展中的作用越來越明顯，基因檢測在診斷、治療和預防中的重要性日益凸顯。

基因測試使醫療保健提供者能夠根據個人的基因譜量身定做治療計劃，提高治療效果並最大限度地減少副作用。基因檢測結果可以指導針對特定呼吸系統疾病的標靶治療的開發，產生更有效、更有針對性的治療方案。

基因檢測可以及早識別高風險族群，及時干預和制定個人化治療計劃。遺傳圖譜可以幫助臨床醫生選擇最合適的治療方法，最大限度地減少試驗方法並改善患者的治療結果。基因檢測支持家庭篩檢，以確定呼吸道疾病的遺傳傾向並採取預防措施。

本報告研究了全球呼吸系統疾病基因檢測市場，提供了市場概述、產品趨勢、疾病類型、技術、性狀類型、年齡層、最終用戶、地區分類的趨勢，和參與市場的公司概況。

目錄

第1章 產品定義

第2章 市場範圍

第3章 調查方法

  • 全球呼吸系統疾病基因檢測市場：調查方法
  • 資料來源
  • 市場估算模型
  • 企業概況標準

第4章 全球呼吸系統疾病基因檢測市場：概述

第5章 全球呼吸系統疾病基因檢測市場：產業分析

  • 概述
  • 法律和法律規範
  • 產品平臺分析
  • 資金籌措方案（2019-2022）
  • 專利分析

第6章 全球呼吸系統疾病基因檢測市場：市場動態

  • 概述
  • 影響分析
  • 市場促進因素
  • 市場抑制因素
  • 市場機會

第7章 全球呼吸系統疾病基因檢測市場：競爭形勢

  • 概述
  • 協同效應
  • 產品發布和增強
  • 產品核准
  • 併購
  • 業務擴展和其他活動
  • 依公司分類的市場佔有率分析（2022年）
  • 成長佔有率分析

第8章 全球呼吸系統疾病基因檢測市場（依產品分類），2022-2033

  • 概述
  • 產品
  • 服務
  • 其他

第9章 全球呼吸系統疾病基因檢測市場（依疾病類型），2022-2033

  • 概述
  • 慢性阻塞性肺病（α-1-抗胰蛋白酶（AAT））
  • 囊腫纖維化（CF）
  • 瀰漫性肺病/肺表面物質功能障礙
  • 間質性肺病
  • 肺動脈高血壓
  • 肺發育不全
  • 原發性纖毛運動異常症
  • 其他疾病（BPD）

第10章 全球呼吸系統疾病基因檢測市場（依技術），2022-2033

  • 概述
  • PCR
  • NGS
  • 其他（標靶定序、核型分析、FISH）

第11章 全球呼吸道疾病基因檢測市場（依性狀類型），2022-2033

  • 概述
  • 遺傳特徵
  • 後天的特徵

第12章 全球呼吸系統疾病基因檢測市場（依年齡層），2022-2033

  • 概述
  • 兒童
  • 成人

第13章 全球呼吸道疾病基因檢測市場（依最終用戶），2022-2033

  • 概述
  • 醫院實驗室
  • 診斷實驗室
  • 基因檢測實驗室
  • 研究機構
  • 其他

第14章 2022-2033年全球呼吸道疾病基因檢測市場（分地區）

  • 概述
  • 成長潛力分析（依國家）
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 其他地區

第15章 公司簡介

  • 23andMe, Inc.
  • Centogene AG
  • GeneDx, Inc.
  • Invitae Corporation
  • Color Genomics
  • Myriad Genetics
  • Medicover Genetics
  • Blueprint Genetics
  • Prevention Genetics
  • Quest Diagnostics
  • Genesis Genetics
  • ARUP Laboratories
  • EGL Genetic Diagnostics
  • Laboratory Corporation of America Holdings（LabCorp）
簡介目錄

Respiratory diseases continue to be a global health concern, with a significant impact on patient well-being and healthcare systems. Genetic testing has emerged as a crucial tool for understanding the genetic underpinnings of various respiratory conditions. This report provides an in-depth analysis of the global and regional trends in the respiratory disease genetic testing market, offering insights into market size, growth trends, regional disparities, and the impact of genetics on respiratory disease diagnostics and treatment.

Introduction

Respiratory diseases represent a diverse group of disorders, including asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and interstitial lung diseases, among others. The role of genetics in respiratory disease development and progression has become increasingly evident, leading to the growing importance of genetic testing in diagnosis, treatment, and prevention.

Market Overview

This section provides an overview of the global respiratory disease genetic testing market, including market size, growth trends, and key drivers.

Market Size and Growth

  • Factors contributing to this growth include the rising prevalence of respiratory diseases, advances in genetic testing technologies, and increasing awareness of personalized medicine.

Global Trends

  • Personalized Medicine: Genetic testing allows healthcare providers to tailor treatment plans to an individual's genetic profile, enhancing treatment efficacy and minimizing adverse effects.
  • Targeted Therapies: Genetic testing results are guiding the development of targeted therapies for specific respiratory diseases, leading to more effective and precise treatment options.
  • Genome-wide Association Studies (GWAS): Ongoing GWAS are identifying novel genetic markers associated with respiratory diseases, expanding our understanding of their genetic basis.

Impact on Diagnosis and Treatment

Genetic testing has a significant impact on the diagnosis and treatment of respiratory diseases.

  • Early Diagnosis: Genetic testing enables early identification of individuals at risk, allowing for timely intervention and personalized treatment plans.
  • Treatment Selection: Genetic profiles help clinicians choose the most suitable therapies, minimizing trial-and-error approaches and improving patient outcomes.
  • Family Screening: Genetic testing supports family screening to identify genetic predispositions to respiratory diseases, allowing for preventative measures.

Challenges and Opportunities

This section outlines the challenges and opportunities within the respiratory disease genetic testing market.

Challenges

  • Ethical and Privacy Concerns: The ethical use of genetic data and privacy concerns continue to be important considerations.
  • Access to Testing: Disparities in access to genetic testing services exist, affecting the equitable provision of care.

Opportunities

  • Advancements in Technology: Ongoing technological advancements are improving the accuracy and affordability of genetic testing.
  • Integration with Healthcare Systems: Integration with electronic health records and healthcare systems is streamlining the use of genetic information in clinical practice.

Table of Contents

1. Product Definition

  • 1.1. Inclusion and Exclusion

2. Market Scope

  • 2.1. Scope of Work
  • 2.2. Key Questions Answered in the Report

3. Research Methodology

  • 3.1. Global Respiratory Disease Genetic Testing Market: Research Methodology
  • 3.2. Data Sources
    • 3.2.1. Primary Data Sources
    • 3.2.2. Secondary Data Sources
  • 3.3. Market Estimation Model
  • 3.4. Criteria for Company Profiling

4. Global Respiratory Disease Genetic Testing Market: Overview

  • 4.1. Market Definition
  • 4.2. Market Footprint and Growth Potential
  • 4.3. Future Potential
  • 4.4. Genetic Surfactant Related Disorders
  • 4.5. Pulmonary Phenotypes and Related Genes
  • 4.6. Practical Issues of Genetic Testing for Respiratory Diseases
  • 4.7. Advantages and Disadvantages of Different Genetic Sequencing Approaches

5. Global Respiratory Disease Genetic Testing Market: Industry Analysis

  • 5.1. Overview
  • 5.2. Legal and Regulatory Framework
    • 5.2.1. Overview
    • 5.2.2. Regulatory Framework in the U.S.
    • 5.2.3. Regulatory Framework in the European Union
    • 5.2.4. Regulatory Framework in Asia
  • 5.3. Product Pipeline Analysis
    • 5.3.1. Overview
    • 5.3.2. By Companies
    • 5.3.3. By Developmental Phase
  • 5.4. Funding Scenario (2019-2022)
    • 5.4.1. Overview
    • 5.4.2. Institutional vs. Academic Funding
  • 5.5. Patent Analysis
    • 5.5.1. Overview
    • 5.5.2. By Country
    • 5.5.3. By Year

6. Global Respiratory Disease Genetic Testing Market: Dynamics

  • 6.1. Overview
  • 6.2. Impact Analysis
  • 6.3. Market Drivers
  • 6.4. Market Restraints
  • 6.5. Market Opportunities

7. Global Respiratory Disease Genetic Testing Market: Competitive Landscape

  • 7.1. Overview
  • 7.2. Synergistic Activities
  • 7.3. Product Launches and Enhancements
  • 7.4. Product Approvals
  • 7.5. Mergers and Acquisitions
  • 7.6. Business Expansion and Other Activities
  • 7.7. Market Share Analysis, By Company (2022)
  • 7.8. Growth Share Analysis
    • 7.8.1. By Application
    • 7.8.2. By Technology

8. Global Respiratory Disease Genetic Testing Market (by Offerings), 2022-2033, ($Million)

  • 8.1. Overview
  • 8.2. Products
    • 8.2.1. Kits and Consumables
  • 8.3. Services
  • 8.4. Others

9. Global Respiratory Disease Genetic Testing Market (by Disease Type), 2022-2033, ($Million)

  • 9.1. Overview
  • 9.2. COPD (Alpha-1-antitrypsin (AAT)
  • 9.3. Cystic Fibrosis (CF)
  • 9.4. Diffuse Lung Disease/Surfactant Dysfunction
    • 9.4.1. RHD (Respiratory Distress Syndrome)
    • 9.4.2. PPHN (Persistent Pulmonary Hypertension of the Newborn)
  • 9.5. Interstitial lung disease
  • 9.6. Pulmonary Arterial Hypertension
  • 9.7. Pulmonary Hypoplasia
  • 9.8. Primary Ciliary Dyskinesia
  • 9.9. Other Diseases (BPD)

10. Global Respiratory Disease Genetic Testing Market (by Technology), 2022-2033, ($Million)

  • 10.1. Overview
  • 10.2. PCR
  • 10.3. NGS
    • 10.3.1. Whole Genome Sequencing
    • 10.3.2. Whole Exome Sequencing
  • 10.4. Others (Targeted Sequencing, Karyotyping, and FISH)

11. Global Respiratory Disease Genetic Testing Market (by Trait Type), 2022-2033, ($Million)

  • 11.1. Overview
  • 11.2. Inherited Trait
  • 11.3. Acquired Trait

12. Global Respiratory Disease Genetic Testing Market (by Age Group), 2022-2033, ($Million)

  • 12.1. Overview
  • 12.2. Children Age Group
  • 12.3. Adult Age Group

13. Global Respiratory Disease Genetic Testing Market (by End User), 2022-2033, ($Million)

  • 13.1. Overview
  • 13.2. Hospital Laboratories
  • 13.3. Diagnostics Laboratories
  • 13.4. Genetic Testing Laboratories
  • 13.5. Research Laboratories
  • 13.6. Other End User

14. Global Respiratory Disease Genetic Testing Market (by Region), 2022-2033, ($Million)

  • 14.1. Overview
  • 14.2. Growth Potential Analysis (by Country)
  • 14.3. North America
    • 14.3.1. Key Dynamics
    • 14.3.2. U.S.
      • 14.3.2.1. By Application
      • 14.3.2.2. By Technology
    • 14.3.3. Canada
      • 14.3.3.1. By Application
      • 14.3.3.2. By Technology
  • 14.4. Europe
    • 14.4.1. Key Dynamics
    • 14.4.2. Italy
      • 14.4.2.1. By Application
      • 14.4.2.2. By Technology
    • 14.4.3. France
      • 14.4.3.1. By Application
      • 14.4.3.2. By Technology
    • 14.4.4. Russia
      • 14.4.4.1. By Application
      • 14.4.4.2. By Technology
    • 14.4.5. Germany
      • 14.4.5.1. By Application
      • 14.4.5.2. By Technology
    • 14.4.6. U.K.
      • 14.4.6.1. By Application
      • 14.4.6.2. By Technology
    • 14.4.7. Spain
      • 14.4.7.1. By Application
      • 14.4.7.2. By Technology
    • 14.4.8. Rest-of-Europe
  • 14.5. Asia-Pacific
    • 14.5.1. Key Dynamics
    • 14.5.2. China
      • 14.5.2.1. By Application
      • 14.5.2.2. By Technology
    • 14.5.3. Japan
      • 14.5.3.1. By Application
      • 14.5.3.2. By Technology
    • 14.5.4. India
      • 14.5.4.1. By Application
      • 14.5.4.2. By Technology
    • 14.5.5. Australia
      • 14.5.5.1. By Application
      • 14.5.5.2. By Technology
    • 14.5.6. Singapore
      • 14.5.6.1. By Application
      • 14.5.6.2. By Technology
    • 14.5.7. South Korea
      • 14.5.7.1. By Application
      • 14.5.7.2. By Technology
    • 14.5.8. Rest-of-Asia-Pacific
  • 14.6. Latin America
    • 14.6.1. Key Dynamics
    • 14.6.2. Brazil
      • 14.6.2.1. By Application
      • 14.6.2.2. By Technology
    • 14.6.3. Mexico
      • 14.6.3.1. By Application
      • 14.6.3.2. By Technology
    • 14.6.4. Rest-of-Latin America
  • 14.7. Rest-of-the-World
    • 14.7.1. Key Dynamics
    • 14.7.2. Middle East and Africa
      • 14.7.2.1. By Application
      • 14.7.2.2. By Technology
    • 14.7.3. Rest-of-Rest-of-the-World

15. Company Profiles

  • 15.1. Overview
  • 15.2. 23andMe, Inc.
  • 15.3. Centogene A.G.
  • 15.4. GeneDx, Inc.
  • 15.5. Invitae Corporation
  • 15.6. Color Genomics
  • 15.7. Myriad Genetics
  • 15.8. Medicover Genetics
  • 15.9. Blueprint Genetics
  • 15.10. Prevention Genetics
  • 15.11. Quest Diagnostics
  • 15.12. Genesis Genetics
  • 15.13. ARUP Laboratories
  • 15.14. EGL Genetic Diagnostics
  • 15.15. Laboratory Corporation of America Holdings (LabCorp)